
PID No. : MED120880221 : 123003029 SID No.

Age / Sex : 40 Year(s) / Female Report On : 25/02/2023 6:11 PM

Printed On

Type : OP

Ref. Dr : MediWheel



: 01/03/2023 1:44 PM




Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> Reference Interval
BLOOD GROUPING AND Rh TYPING	'O' 'Positive'		
(EDTA Blood/Agglutination)			
INTERPRETATION: Reconfirm the Blood grou	p and Typing before	e blood transfusion	
Complete Blood Count With - ESR			
Haemoglobin (EDTA Blood/Spectrophotometry)	12.2	g/dL	12.5 - 16.0
Packed Cell Volume(PCV)/Haematocrit (EDTA Blood/Derived from Impedance)	38.8	%	37 - 47
RBC Count (EDTA Blood/Impedance Variation)	4.58	mill/cu.mm	4.2 - 5.4
Mean Corpuscular Volume(MCV) (EDTA Blood/Derived from Impedance)	84.6	fL	78 - 100
Mean Corpuscular Haemoglobin(MCH) (EDTA Blood/Derived from Impedance)	26.6	pg	27 - 32
Mean Corpuscular Haemoglobin concentration(MCHC) (EDTA Blood/Derived from Impedance)	31.5	g/dL	32 - 36
RDW-CV (EDTA Blood/Derived from Impedance)	14.9	%	11.5 - 16.0
RDW-SD (EDTA Blood/Derived from Impedance)	44.12	fL	39 - 46
Total Leukocyte Count (TC) (EDTA Blood/Impedance Variation)	8430	cells/cu.mm	4000 - 11000
Neutrophils (EDTA Blood/Impedance Variation & Flow Cytometry)	57.6	%	40 - 75
Lymphocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	33.9	%	20 - 45
Eosinophils (EDTA Blood/Impedance Variation & Flow	3.4	%	01 - 06



Cytometry)





APPROVED BY

The results pertain to sample tested.

Page 1 of 7

 PID No.
 : MED120880221
 Register On
 : 25/02/2023 9:13 AM

 SID No.
 : 123003029
 Collection On
 : 25/02/2023 10:05 AM

 Age / Sex
 : 40 Year(s) / Female
 Report On
 : 25/02/2023 6:11 PM

Type : OP **Printed On** : 01/03/2023 1:44 PM

Ref. Dr : MediWheel



Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> Reference Interval
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	4.9	%	01 - 10
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.2	%	00 - 02
INTERPRETATION: Tests done on Automated	Five Part cell count	er. All abnormal results a	re reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	4.86	10^3 / μl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.86	10^3 / μΙ	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.29	10^3 / μl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.41	10^3 / μl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.02	10^3 / μl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	354	10^3 / μl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	9.5	fL	8.0 - 13.3
PCT (EDTA Blood/Automated Blood cell Counter)	0.34	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	13	mm/hr	< 20
BUN / Creatinine Ratio	13.8		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	104.9	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126







APPROVED BY

The results pertain to sample tested.

Page 2 of 7

 PID No.
 : MED120880221
 Register On
 : 25/02/2023 9:13 AM

 SID No.
 : 123003029
 Collection On
 : 25/02/2023 10:05 AM

 Age / Sex
 : 40 Year(s) / Female
 Report On
 : 25/02/2023 6:11 PM

Type : OP Printed On : 01/03/2023 1:44 PM

Ref. Dr : MediWheel



<u>Investigation</u>	<u>Observed</u> <u>Unit</u>	<u>Biological</u>
	<u>Value</u>	Reference Interval

INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine) (Urine - F/GOD - POD)	Negative		Negative
Glucose Postprandial (PPBS)	121.7	mg/dL	70 - 140

(Plasma - PP/GOD-PAP)

INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

Urine Glucose(PP-2 hours) (Urine - PP)	Negative		Negative
Blood Urea Nitrogen (BUN) (Serum/Urease UV / derived)	11.1	mg/dL	7.0 - 21
Creatinine (Serum/Modified Jaffe)	0.80	mg/dL	0.6 - 1.1

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin, cefazolin, ACE inhibitors, angiotensin II receptor antagonists,N-acetylcysteine, chemotherapeutic agent such as flucytosine etc.

Uric Acid (Serum/Enzymatic) Liver Function Test	5.5	mg/dL	2.6 - 6.0
Liver Function Test			
Bilirubin(Total) (Serum/DCA with ATCS)	0.28	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.10	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.18	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase) (Serum/Modified IFCC)	13.5	U/L	5 - 40

11.8



SGPT/ALT (Alanine Aminotransferase)

(Serum/Modified IFCC)



U/L



5 - 41

APPROVED BY

The results pertain to sample tested.

Page 3 of 7

 PID No.
 : MED120880221
 Register On
 : 25/02/2023 9:13 AM

 SID No.
 : 123003029
 Collection On
 : 25/02/2023 10:05 AM

 Age / Sex
 : 40 Year(s) / Female
 Report On
 : 25/02/2023 6:11 PM

Type : OP Printed On : 01/03/2023 1:44 PM

Ref. Dr : MediWheel



Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	5.6	U/L	< 38
Alkaline Phosphatase (SAP) (Serum/Modified IFCC)	85.0	U/L	42 - 98
Total Protein (Serum/Biuret)	7.40	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.24	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	3.16	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived)	1.34		1.1 - 2.2
<u>Lipid Profile</u>			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	147.0	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	55.3	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the `usual_circulating level of triglycerides during most part of the day.

HDL Cholesterol 45.9 mg/dL Optimal(Negative Risk Factor): >= (Serum/Immunoinhibition) 60

Borderline: 50 - 59 High Risk: < 50







APPROVED BY

PID No. : MED120880221

SID No. : 123003029

Age / Sex : 40 Year(s) / Female

Type : OP

Ref. Dr : MediWheel

Register On : 25/02/2023 9:13 AM

Collection On : 25/02/2023 10:05 AM

: 25/02/2023 6:11 PM

Report On

Printed On : 01/03/2023 1:44 PM



Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
LDL Cholesterol (Serum/Calculated)	90	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	11.1	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	101.1	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

INTERPRETATION: 1. Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2. It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

1 , 2	1 3		
Total Cholesterol/HDL Cholesterol Ratio (Serum/Calculated)	3.2		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/Calculated)	1.2		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	2		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
Glycosylated Haemoglobin (HbA1c)			
HbA1C (Whole Blood/ <i>HPLC</i>)	6.1	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5

INTERPRETATION: If Diabetes - Good control: 6.1 - 7.0 %, Fair control: 7.1 - 8.0 %, Poor control >= 8.1 %







APPROVED BY

The results pertain to sample tested.

Page 5 of 7

 PID No.
 : MED120880221
 Register On
 : 25/02/2023 9:13 AM

 SID No.
 : 123003029
 Collection On
 : 25/02/2023 10:05 AM

Printed On

Ref. Dr : MediWheel

: OP

Type

: 25/02/2023 6:11 PM : 01/03/2023 1:44 PM

medall

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Estimated Average Glucose	128.37	mg/dL	
(Whole Blood)			

INTERPRETATION: Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbAlC values.

Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.

THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total 1.42 ng/ml 0.7 - 2.04

(Serum/Chemiluminescent Immunometric Assay (CLIA))

INTERPRETATION:

Comment:

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.

T4 (Tyroxine) - Total 7.99 $\mu g/dl$ 4.2 - 12.0

(Serum/Chemiluminescent Immunometric Assay

(CLIA))

INTERPRETATION:

Comment:

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

TSH (Thyroid Stimulating Hormone) 2.69 µIU/mL 0.35 - 5.50

(Serum/Chemiluminescent Immunometric Assay

(CLIA))

INTERPRETATION:

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0

(Indian Thyroid Society Guidelines)

Comment:

1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.

2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.

3. Values&lt 0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.







APPROVED BY

The results pertain to sample tested.

Page 6 of 7

Lab Address: MEDALL HEALTHCARE PRIVATE LIMITED,#17,RACE VIEW COLONY, 2ND STREET, RACE COURSE ROAD, GUINDY, CHENNAI, TAMIL NADU, INDIA,.

 PID No.
 : MED120880221
 Register On
 : 25/02/2023 9:13 AM

 SID No.
 : 123003029
 Collection On
 : 25/02/2023 10:05 AM

 Age / Sex
 : 40 Year(s) / Female
 Report On
 : 25/02/2023 6:11 PM

Printed On : 01/03/2023 1:44 PM

Ref. Dr : MediWheel

: OP

Type



Investigation Urine Analysis - Routine	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Orine Analysis - Rouline			
COLOUR (Urine)	Pale yellow		Yellow to Amber
APPEARANCE (Urine)	Clear		Clear
Protein (Urine/Protein error of indicator)	Negative		Negative
Glucose (Urine/GOD - POD)	Negative		Negative
Pus Cells (Urine/Automated Flow cytometry)	1 - 2	/hpf	NIL
Epithelial Cells (Urine/Automated Flow cytometry)	2 - 3	/hpf	NIL
RBCs (Urine/Automated Flow cytometry)	1 - 2	/hpf	NIL
Casts (Urine/Automated Flow cytometry)	NIL	/hpf	NIL
Crystals (Urine/Automated Flow cytometry)	NIL	/hpf	NIL
Others (Urine)	NIL		

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.







APPROVED BY

-- End of Report --





Name	Ms.PONMALAR	ID	MED120880221
Age & Gender	40/FEMALE	Visit Date	25/02/2023
Ref Doctor Name	MediWheel		

ULTRA SOUND SCAN

WHOLE ABDOMEN

Liver is normal in size and shows uniform echotexture with no focal abnormality. There is no intra or extra hepatic biliary ductal dilatation. Portal vein and IVC are normal.

Gall bladder is not visualized - H/o. Surgery.

Pancreas shows a normal configuration and echotexture. Pancreatic duct is normal.

Spleen is normal in size and echotexture.

Bilateral kidneys are normal in size, shape and position. Cortical echoes are normal bilaterally. There is no calculus or calyceal dilatation.

Right kidney measures 9.7 x 3.9 cm.

Left kidney measures 10.9 x 3.9 cm.

Ureters are not dilated.

No abnormality is seen in the region of the **adrenal glands**.

No para aortic lymphadenopathy is seen.

Urinary bladder is smooth walled and uniformly transonic. No intravesical mass or calculus.

Uterus is anteverted, and measures 10.2 x 5.9 x 4.1 cm.

Endometrium appears thickened and measures 10.5 mm.

Right ovary measures 4.3 x 2.2 cm.

No significant mass or cyst is seen in the right ovary.

REPORT DISCLAIMER

- 1. This is only a radiologincal imperssion. Like other investigations, radiological investication also have limitation. Therefore radiologincal reports should be interpreted in correlation with clinical and pathological findings.
- $2. The \ results \ reported \ here \ in \ are \ subject \ to \ interpretation \ by \ qualified \ medical \ professionals \ only.$
- 3. Customer identities are accepted provided by the customer or their representative.
- 4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.
- 5.If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.
- 6.Test results should be interpreted in context of clinical and other findings if any. In case of any clarification /doubt, the refrering doctor/patient can contact the respective section head of the laboratory.
- 7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,
- 8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.
- 9.Liability is limited to the extend of amount billed.
- 10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.
- 11.Disputes, if any , with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.





Name	Ms.PONMALAR	ID	MED120880221
Age & Gender	40/FEMALE	Visit Date	25/02/2023
Ref Doctor Name	MediWheel		

Left ovary measures 7.1 x 4.6 cm and has a chocolate cyst measuring 4.5 x 3.5 cm.

Parametria are free.

Iliac fossae are normal.

There is no free or loculated peritoneal fluid.

IMPRESSION:

- Post cholecystectomy status.
- > Thickened endometrium.
- > Chocolate cyst in left ovary.
 - --- Suggested clinical correlation.

Dr. SUMITHA SONOLOGIST

REPORT DISCLAIMER

- 1. This is only a radiologincal imperssion. Like other investigations, radiological investication also have limitation. Therefore radiologincal reports should be interpreted in correlation with clinical and pathological findings.
- 2. The results reported here in are subject to interpretation by qualified medical professionals only.
- 3. Customer identities are accepted provided by the customer or their representative.
- 4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.
- 5.If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.
- 6.Test results should be interpreted in context of clinical and other findings if any. In case of any clarification /doubt, the refrering doctor/patient can contact the respective section head of the laboratory.
- 7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,
- 8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.
- 9.Liability is limited to the extend of amount billed.
- 10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.
- 11.Disputes,if any , with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.